ReviewFrontiers in global women's health2026
Expanding treatment options for syphilis during pregnancy: a review of alternatives to penicillin.
Review in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syphilis infection during pregnancy leads to around 390,000 adverse birth outcomes each year and is an important cause of preventable stillbirth. Although benzathine penicillin G is safe and effective during pregnancy for treating maternal and fetal infection, there are frequent global shortages and limited options for people with penicillin allergy. We conducted a review of potential alternatives to penicillin for treating syphilis during pregnancy when penicillin is not available or cannot be used, including ceftriaxone, amoxicillin, doxycycline, cefixime, and linezolid. Despite some efficacy data on their use in non-pregnant adults with syphilis, limited data were available on placental transfer, pharmacokinetics and dosing, efficacy or effectiveness, and safety in pregnancy. Given its favourable preclinical reproductive toxicity data, efficacy data in non-pregnant adults with syphilis, and safety during pregnancy when used for other indications, ceftriaxone could potentially be considered as an alternative treatment for pregnant women with syphilis in cases where penicillin cannot be used, as currently recommended by the World Health Organization. However, evidence about optimal dosing, feasibility, and efficacy/effectiveness for treating syphilis during pregnancy is needed. Several planned and ongoing clinical trials will provide additional data to inform the use of cefixime, amoxicillin, and linezolid in pregnant women with syphilis. Going forward, evaluation of new and existing medications for treating syphilis and preventing congenital syphilis should include a pregnancy investigation plan. Where possible, efforts should be made to ensure that high-quality pregnancy safety and efficacy or effectiveness data on drug candidates are generated in carefully designed studies to ensure that pregnant women and their infants are able to benefit from the full range of treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.